TY - JOUR
T1 - Life projects
T2 - the transformative potential of direct-acting antiviral treatment for hepatitis C among people who inject drugs
AU - E. Williams, Beth
AU - Nelons, Devynne
AU - Seaman, Andrew
AU - Witkowska, Martyna
AU - Ronan, Wren
AU - Wheelock, H.
AU - Zaman, Atif
AU - Garcia, Jonathan
N1 - Funding Information:
Merck pharmaceuticals provided financial support for this study. Merck did not have a direct role in the study design, data collection, or analysis of this research. We would like to thank the individuals who shared their experiences for the purpose of this study.
Publisher Copyright:
© 2019 Elsevier B.V.
PY - 2019/10
Y1 - 2019/10
N2 - Background and objectives: People who inject drugs (PWID) are disproportionately affected by chronic hepatitis C (HCV) in high-income countries. The advent of direct-acting antivirals (DAAs) makes treatment of this underserved population more possible than ever. The dearth of programs adapted to the needs of PWID and stigma associated with drug use and chronic HCV pose significant barriers to the effective uptake of treatment among this population. We employed “life projects” as a conceptual framework to examine the social incentives of PWID being treated for HCV. This study advances the existing literature on the transformative potential of HCV treatment among PWID, explores how these transformations may affect treatment success, and discusses implications for decisions around whether and when to treat PWID. Methods: We conducted in-depth interviews with participants of a pilot clinical trial testing the effective delivery of DAA treatment to PWID within two healthcare for the homeless clinic settings – one group receiving opioid agonist therapy (OAT) and another group frequenting a needle and syringe exchange program (NSP). A purposive sample of 27 participants was selected based on place of care. Interviews were transcribed, coded, and analysed for patterns using a priori domains and emergent themes. Results: Participants in both treatment groups described significant life projects that motivated them to complete HCV treatment. These projects included social redemption, strengthening of relationships, pursuit of abstinence from substance use, and harm reduction. These themes were consistent between treatment groups, though more participants in the syringe exchange group relied on harm reduction than on pursuing abstinence to prevent reinfection after achieving virologic cure. Conclusion: Understanding the incentives that propel PWID to complete HCV treatment could help to enhance treatment uptake and adherence through dedicated programs that address current barriers to care.
AB - Background and objectives: People who inject drugs (PWID) are disproportionately affected by chronic hepatitis C (HCV) in high-income countries. The advent of direct-acting antivirals (DAAs) makes treatment of this underserved population more possible than ever. The dearth of programs adapted to the needs of PWID and stigma associated with drug use and chronic HCV pose significant barriers to the effective uptake of treatment among this population. We employed “life projects” as a conceptual framework to examine the social incentives of PWID being treated for HCV. This study advances the existing literature on the transformative potential of HCV treatment among PWID, explores how these transformations may affect treatment success, and discusses implications for decisions around whether and when to treat PWID. Methods: We conducted in-depth interviews with participants of a pilot clinical trial testing the effective delivery of DAA treatment to PWID within two healthcare for the homeless clinic settings – one group receiving opioid agonist therapy (OAT) and another group frequenting a needle and syringe exchange program (NSP). A purposive sample of 27 participants was selected based on place of care. Interviews were transcribed, coded, and analysed for patterns using a priori domains and emergent themes. Results: Participants in both treatment groups described significant life projects that motivated them to complete HCV treatment. These projects included social redemption, strengthening of relationships, pursuit of abstinence from substance use, and harm reduction. These themes were consistent between treatment groups, though more participants in the syringe exchange group relied on harm reduction than on pursuing abstinence to prevent reinfection after achieving virologic cure. Conclusion: Understanding the incentives that propel PWID to complete HCV treatment could help to enhance treatment uptake and adherence through dedicated programs that address current barriers to care.
KW - HCV
KW - Harm reduction
KW - Hepatitis C treatment
KW - Life projects
KW - People who inject drugs
KW - Qualitative research
UR - http://www.scopus.com/inward/record.url?scp=85064204861&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85064204861&partnerID=8YFLogxK
U2 - 10.1016/j.drugpo.2019.03.015
DO - 10.1016/j.drugpo.2019.03.015
M3 - Article
C2 - 30995968
AN - SCOPUS:85064204861
SN - 0955-3959
VL - 72
SP - 138
EP - 145
JO - International Journal of Drug Policy
JF - International Journal of Drug Policy
ER -